FORKNOW® TABLET

Forknow (Flunarizine) is a class IV calcium antagonist with a pharmacological profile which suggests its therapeutic potential in a number of neurological and cerebrovascular disorders.

Ingredient(s):

Each tablet contains:

Flunarizine (as Flunarizine Hydrochloride) 10mg

Action(s):

- Flunarizine is a class IV calcium antagonist which reduces the transmembrane fluxes of calcium in situations where calcium is stimulated to enter the cell in excess, thus preventing the deleterious consequences of "calcium overload" within the cell.
- 2. Flunarizine is a selective calcium-entry blocker with a similar chemical structure and pharmacology profile to related compound, Cinnarizine. However, in contrast to Cinnarizine, it has long plasma half-life and needs only be given once a day. The majority of therapeutic trials in the prophylaxis of migraine, occlusive peripheral vascular disease and vertigo of central peripheral origin have been placebo-controlled and have been shown that Flunarizine produces significantly greater beneficial effects than placebo as evaluated by subjective and objective criteria.
- 3. Flunarizine has also demonstrated vestibular depressive, antihistaminic, and anticonvulsant effects in human or animal.
- 4. Peak concentration levels occur 2 to 4 hours after oral administration of Flunarizine in healthy subjects. 0.8% of Flunarizine is present as free drug in plasma, 90% being bound to plasma proteins and 9% in blood cells. In healthy subjects Flunarizine is removed from the body with a long elimination half-life of around 18 days.

Indication(s):

For prophylaxis of migraine, peripheral venous insufficiency and occlusive arterial disease.

Dosage and Administration:

The usual dose for adults: 10mg tablet once daily preferably at night on retiring.

Precaution(s) / Warning(s):

Flunarizine should be used with caution in patients with liver dysfunction and blood coagulating disorders.

Contraindication(s):

- 1. Patients known to be hypersensitive to this drug.
- There is, as yet, no evidence of embryotoxic effects of Flunarizine in experimental animals. Nevertheless, the anticipated therapeutic benefits should be weighed against potential hazards before administering the compound during pregnancy.

Side Effect(s) / Adverse Reaction(s):

Asthenia, weight gain, migraine, drowsiness, depression, gastric pain, nausea, dry mouth, insomnia and rashes.

260mm (±2mm)

Item Code	: 204xxxdraft 09 May 2022
PM Code	: Ins.P FKT (S)
Measurement(mm) ± 2mm	: 260(L) x 110(W)
CURSOR (ATTACHMENT 1)	: mm
CURSOR (ATTACHMENT 2)	: mm
Colour of Artwork	: K 100
Source of Artwork	: MAC 3 / CC

Symptoms and Treatment for Overdosage, and Antidote(s):

There is no specific antidote for its overdose, therefore, management of the patient consists of symptomatic and supportive therapy.

Storage Condition(s):

Keep in a tight container. Store at temperature below 30°C. Protect from light and moisture.

Shelf-Life:

3 years from the date of manufacture.

Packing(s):

Plastic bottle of 150's, 500's and 1000's. Blister packing of 10's x 10, 10's x 100 (Not all pack sizes may be available)

> The information contained in this leaflet is limited. Further information can be obtained from other sources including your doctor or pharmacist.

260mm (±2mm)



Manufacturer and Product Registration Holder: Y.S.P. INDUSTRIES (M) SDN. BHD. (199001001034) Lot 3, 5 & 7, Jalan P/7, Section 13, Kawasan Perindustrian Bandar Baru Bangi, 43000 Kajang, Selangor Darul Ehsan, Malaysia.

Product Registrant and Importer: YUNG SHIN PHARMACEUTICAL (S) PTE. LTD. 10 Ubi Crescent, #06-57/85 Ubi Tech Park, Singapore 408564.

xxxxxx printing code xxxxxx

Date of revision: 09 May 2022

Item Code	: 204xxxdraft 09 May 2022
PM Code	: Ins.P FKT (S)
Measurement(mm) ± 2mm	: 260(L) x 110(W)
CURSOR (ATTACHMENT 1)	: mm
CURSOR (ATTACHMENT 2)	: mm
Colour of Artwork	: K 100
Source of Artwork	: MAC 3 / CC